Founded in 2005, Korea Institute for Pharmaceutical Policy Affairs, KIPPA, is a non-profit, public foundation, approved by the Korean Ministry of Health and Welfare. The institute is contributed by three relevant parties, the Korean Pharmaceutical Association (KPA), the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KBPMA), and the Korea Pharmaceutical Distribution Association (KPDA).

KIPPA is a leading research center, which aims to promote public health through the development of policy regarding the rational use of medicines, pharmacy education, pharmacy practice, pharmaceutical industry, and pharmaceutical supply and distribution. In particular, we begin to develop ¡®a community pharmacy model as a health promotion center for community members¡¯. We are collecting and analysing big data accordingly to develop pharmacy-based policies, which pursue maximised pharmacy practice for all the Koreans.

In consequence, KIPPA will consistently implement research tailored to the promotion of health in the nation and worldwide. We kindly ask for supports from our fellow pharmacists, public and associations.

If you have any further enquiries about the institute or research in English, please contact us via e-mail (kippa.org@gmail.com).

Thank you.

Office Address
3FL, 194, Hyoryeong-ro, Seocho-gu, Seoul, Repbulic of Korea

ÇöÀçÀ§Ä¡ : Home : ¾Ë¸²¸¶´ç : ¿¬±¸¼Ò ´º½º
   
¾Ë¸²¸¶´ç
°øÁö»çÇ×
º¸µµÀÚ·á
ÀÎÀçä¿ë
 
 
Á¦   ¸ñ [´ëÇѾà»çÀú³Î] ¹Ì·¡¾à±¹¼­ºñ½º »ç·Ê¿¬±¸ <1>
³»   ¿ë

¹Ì·¡¾à±¹¼­ºñ½º »ç·Ê¿¬±¸ <1>

ÁÖ¿ä ¿Ü±¹¿¡¼­ÀÇ Ä¡¸Å°ü¸®¼­ºñ½º ¸ðµ¨ °³¹ßÀ» Áß½ÉÀ¸·Î


ÃÖ±Ù ±Þ¼ÓÇÑ °í·ÉÈ­¿¡ µû¸¥ ³ëÀÎÁúȯÀΠġ¸ÅÀ¯º´·ü ¶ÇÇÑ ±Þ¼ÓÈ÷ Áõ°¡ÇÔ¿¡ µû¶ó ¿À´Â 2025³â¿¡´Â Ä¡¸ÅÀα¸°¡ 100¸¸ ¸íÀ» ³Ñ¾î¼³ °ÍÀ¸·Î ¿¹»óµÇ´Â µî ´õ ÀÌ»ó Ä¡¸Å°¡ °³Àΰú °¡Á·µéÀÇ ¹®Á¦°¡ ¾Æ´Ñ »çȸ¹®Á¦·Î Àνĵǰí Àִ ¹Ù, Ä¡¸Å¸¦ ¾Î°í Àִ ³ëÀεéÀ» ´ë»óÀ¸·Î ÇÑ º°µµÀÇ Ä¿¹Â´ÏƼÄɾºñ½º°¡ ¿ä±¸µÇ°í ÀÖ´Ù.  

±×·¯³ª ÇöÀç ÃßÁøµÇ°í Àִ Á¤ºÎÀÇ Ä¿¹Â´ÏƼÄɾëÀμ±µµ»ç¾÷Àº ÁÖ°ÅÁö¿ø, ¸¸¼ºÁúȯ°ü¸®, ¹æ¹®Áø·á, º¸°Ç¼Ò °Ç°­°ü¸®¼­ºñ½º, Àå±â¿ä¾ç, Àç°¡ ÀÇ·á±Þ¿© µî ÀÔ¿øÈ¯ÀÚ Áß Áö¿ª»çȸ º¹±Í¸¦ Èñ¸ÁÇϴ ³ëÀÎÀ» ´ë»óÀ¸·Î ÇÑ ¼­ºñ½º¿¡ ÁýÁߵǾî ÀÖ°í, ½Ã¼³ ÀÔ¼Ò Àü Ãʱ⠶Ǵ °æÁõÄ¡¸Å ³ëÀÎÀ» ´ë»óÀ¸·Î ÇÑ ¸ÂÃãÇü °Ç°­°ü¸® µî°ú °°Àº Á¦µµÀû ÀÎÇÁ¶ó ±¸ÃàÀº ¾ÆÁ÷ ¹ÌÈíÇÑ ½ÇÁ¤ÀÌ´Ù.    

¿ì¸®³ª¶ó´Â 2017³â ¡®Ä¡¸Å±¹°¡Ã¥ÀÓÁ¦¡¯°¡ µµÀԵȠÀÌ·¡, Àü±¹ 256°³¼ÒÀÇ Ä¡¸Å¾È½É¼¾ÅͰ¡ ¼³¸³µÇ´Â µî ±¹°¡Â÷¿øÀÇ Ä¡¸Å ±Øº¹À» À§ÇÑ ÁßÀå±â °èȹÀ» ¼ö¸³Çϰí Ä¡¸ÅȯÀÚ¿¡ ´ëÇÑ È¿°úÀûÀΠ°Ç°­°ü¸® ¹× µ¹º½ ºÎ´ã ¿ÏÈ­¸¦ À§ÇÑ ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÁö¸¸, ¾ÆÁ÷±îÁö Áö¿ª»çȸ µ¹º½ ÀÎÇÁ¶óÀÇ ÇÑ ÃàÀ̶ó ÇÒ ¼ö Àִ Áö¿ª¾à±¹°úÀÇ Çù·ÂüÁ¦ ±¸ÃàÀÌ Àß ÀÌ·ç¾îÁö°í ÀÖÁö ¾ÊÀº »óȲÀ̶ó ÇϰڴÙ.  

¾à±¹Àº °ø°£(½Ã¼³ÀÌ ¾Æ´Ñ Áö¿ª»çȸ µ¹º½)À¸·Î¼­ÀÇ Ä¿¹Â´ÏƼÄɾî¿Í ÀÚ¿ø(Áö¿ª»çȸ¿¡ Á¸ÀçÇϴ ÀǷᠽü³, ¿ä¾ç ½Ã¼³ µîÀÇ °ø½Ä µ¹º½ Ã¼°è)À¸·Î¼­ÀÇ Ä¿¹Â´ÏƼÄɾ ¸ðµÎ ÇØ´çµÉ »Ó¸¸ ¾Æ´Ï¶ó, º¸°ÇÀÇ·á¼­ºñ½º, »çȸÀûÁöÁö, ¼­ºñ½º Á¶Á¤, ¼­ºñ½º È¥ÇÕÀÇ ¿µ¿ª¿¡¼­ ¿ªÇÒÀ» ¸ðµÎ ¼öÇàÇÒ ¼ö Àֱ⠶§¹®¿¡ ¾à±¹¿¡¼­ÀÇ Ä¡¸Å°ü¸® ¼­ºñ½º ¸ðµ¨ °³¹ßÀÌ ÇÊ¿äÇÏ´Ù°í º¼ ¼ö ÀÖ´Ù. 

ÀÌ¿¡ ÇöÀç ±¹³» ±¹³»¿Ü¿¡¼­ Á¦°øµÇ°í Àִ ³ëÀÎÄ¡¸Å ¿¹¹æ ¹× °ü¸®¸¦ À§ÇÑ Áö¿ªÅëÇÕ µ¹º½¼­ºñ½º ÇöȲ¿¡ ´ëÇØ Á¤È®È÷ ÆÄ¾ÇÇϰí, Ä¡¸Å ³ëÀÎÀÇ »îÀÇ Áú Çâ»óÀ» À§ÇÑ ³ë·Âµé¿¡ ÀÖ¾î Áö¿ª»çȸ Á¢±Ù¼ºÀÌ ¶Ù¾î³­ ¾à±¹ÀÌ »õ·Ó°Ô Âü¿©ÇÏ°í ±â¿©ÇÒ ¼ö ÀÖµµ·Ï Çϴ Á¤Ã¥Àû °í¹ÎÀÌ ÇÊ¿äÇÒ °ÍÀ¸·Î »ç·áµÈ´Ù. 

µû¶ó¼­ º» °í¿¡¼­´Â ¡®Ä¡¸Å³ëÀÎÀ» ´ë»óÀ¸·Î Æ¯È­µÈ ¾à±¹ Ä¡¸Å°ü¸®¼­ºñ½º ¸ðµ¨ Á¦½Ã¡¯¸¦ ¸ñÀûÀ¸·Î ¼öÇàÇÑ ±¹³» Ä¡¸Å°ü·Ã Á¤Ã¥ ¼Ò°³ ¹× Áֿ䠿ܱ¹ÀÇ ¾à±¹¿¡¼­ÀÇ Ä¡¸Å°ü¸®¼­ºñ½º ÇöȲ¿¡ ´ëÇÑ ¹®Çå °íÂû ³»¿ëÀ» ¼Ò°³ÇϰíÀÚ ÇÑ´Ù. 

2026³â, Çѱ¹ Ãʰí·É»çȸ ÁøÀÔ
Çѱ¹Àº ÇöÀç °í·É»çȸ·Î µé¾î¼± »óÅ·Î, 2026³â¿¡´Â 65¼¼ ÀÌ»ó °í·ÉÀα¸°¡ ÃÑÀα¸¿¡¼­ Â÷ÁöÇϴ ºñÀ²ÀÌ 20% ÀÌ»óÀΠÃʰí·É»çȸ¿¡ ÁøÀÔÇÒ °ÍÀ¸·Î ¿¹»óµÈ´Ù.
 
Çѱ¹º¸´Ù ¸ÕÀú °í·É»çȸ¿¡ ÁøÀÔÇß´ø ÀϺ»Àº 2005³âºÎÅÍ À̹̠Ãʰí·É»çȸ·Î Á¢¾îµé¾úÀ¸³ª, Ãʰí·É»çȸ·Î °¡´Â ¼Óµµ°¡ ÀϺ»º¸´Ù Çѱ¹ÀÌ ´õ ºü¸£´Ù´Â °Í¿¡¼­ ¹®Á¦ÀÇ ½É°¢¼ºÀ» ¾Ë ¼ö ÀÖ´Ù.  

2019³â Åë°èûÀÌ ¹ßÇ¥ÇÑ ÀÚ·á¿¡ µû¸£¸é Çѱ¹ÀÇ °í·ÉÀα¸ÀÇ ºñÀ²Àº ¸Å¿ì ºü¸¥ ¼Óµµ·Î Áõ°¡ÇØ 2045³â¿¡´Â ¼¼°è¿¡¼­ 65¼¼ ÀÌ»ó °í·ÉÀα¸ ºñÁßÀÌ °¡Àå ³ôÀº ±¹°¡°¡ µÇ¸ç, 2067³â¿¡´Â 65¼¼ Àα¸ ºñÁßÀÌ 47%±îÁö Ä¡¼Ú´Â´Ù. 

Çѱ¹ÀÇ °í·ÉÀα¸ºñÀ²ÀÇ Áõ°¡·Î ÀÎÇÑ »çȸÀû ¹®Á¦´Â ´Ù¸¥ ³ª¶ó¿¡ ºñÇØ¼­µµ ¸Å¿ì ½É°¢ÇÏ´Ù°í ÇÒ ¼ö ÀÖ¾î À̿͠°ü·ÃÇÑ °³ÀÎÀû¡¤»çȸÀû Áغñ°¡ ÇÊ¿äÇÏ´Ù. <±×¸²1>


65¼¼ ÀÌ»ó Ä¡¸ÅȯÀÚÀ¯º´·ü 10.3%
ÇöÀç 65¼¼ ÀÌ»ó Ä¡¸ÅȯÀڴ 76¸¸¸íÀ¸·Î, 65¼¼ ³ëÀÎÀα¸ÀÇ 10%°¡ Ä¡¸ÅȯÀÚÀΠ¼ÀÀÌ´Ù. ¼ºº° Ä¡¸ÅȯÀÚ ºñÀ²À» »ìÆìº¸¸é ³²¼º(37%)º¸´Ù´Â ¿©¼º(63%)ÀÇ ºñÀ²ÀÌ ³ô°í, ¿¬·Éº° ¹ßº´·üÀ» º¸¸é 80¼¼ ÀÌ»óÀÌ 60%¸¦ Â÷ÁöÇÑ´Ù. 

ÁßÁõµµº° ±¸¼ºÀ» »ìÆìº¸¸é, °æµµ°¡ 41.4%À̰í, ÃÖ°æµµ°¡ 17.4%·Î Ä¡¸ÅȯÀÚÀÇ ¾à 60%°¡ Ä¡¸ÅÁ¤µµ°¡ °æµµ ¹× ÃÖ°æµµÀΠ»óȲ¿¡ ³õ¿©ÀÖ´Ù.


<±×¸²2> ÀÌó·³ Ä¡¸ÅȯÀÚ¼ö¿Í À¯º´·üÀÌ °è¼Ó Áõ°¡ÇÔ¿¡ µû¶ó 2024³â¿¡´Â 100¸¸¸í, 2040³â¿¡´Â 200¸¸¸í, 2050³â¿¡´Â 300¸¸¸íÀ» ³Ñ¾î¼³ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ´Ù.<±×¸²3> <´ÙÀ½È£¿¡ °è¼Ó>

[±â»çÃâó] https://www.kpanews.co.kr/academy/show.asp?page=1&search_cate=8&idx=368

 

¹øÈ£ ÷ºÎ Á¦¸ñ ÀÛ¼ºÀÚ ÀÛ¼ºÀÏ Á¶È¸
92 [¸ÞµðÆÄ³ª´º½º]'Äڷγª19 ´ëÀÀ¡¤ÅëÇÕµ¹º½' ´Ù·é ÀǾàǰÁ¤Ã¥¿¬±¸ ¹ß°£  ±è¼±Èñ 2021-01-19 4
91 [¾à»ç°ø·Ð] ¾à±¹ °ÅÁ¡ Àڻ쿹¹æ»ç¾÷, »ý¸íÁöÅ´ÀÌ ¿ªÇÒ 'ÅåÅå'  ±è¼±Èñ 2021-01-19 3
90 [µ¥Àϸ®ÆÊ] ÀϺ»¾à±¹ÀÇ ÁøÈ­¡¦Ä«µå·Î 'Áߺ¹Åõ¾à¡¤³²Àº ¾à °ü¸®±îÁö'  ±è¼±Èñ 2021-01-19 6
89 [´ëÇѾà»çÀú³Î] ¼¼ÀÌÇÁ¾à±¹¡¤¹æ¹®¾à·á µî Ȱµ¿ Áö¼Ó Áõ°¡  ÀÌÁö¿¬ 2021-01-19 3
88 [´ëÇѾà»çÀú³Î] ¾à±¹ ó¹æÁýÁßµµ º¯È­¿Í ¾à±¹¾à»çÀÇ »çȸÀû ¿ªÇÒ Ãß±¸ ÀÌÁö¿¬ 2021-01-13 47
87 [´ëÇѾà»çÀú³Î] ÀåÁ¡Àº Ű¿ì°í ´ÜÁ¡Àº ¾ø¾Ö´Â ±³À°¹æ¹ýÀº? ÀÌÁö¿¬ 2021-01-06 79
86 [´ëÇѾà»çÀú³Î] 'Àڱ⠹ݿµ ¾ç½Ä' ÅëÇØ ¾à±¹ Àü¹®°¡ ±âÁØ ÆÄ¾Ç ÀÌÁö¿¬ 2020-12-29 81
85 [´ëÇѾà»çÀú³Î] CPD °³³ä µîÀå 80³â, ¿ì¸®³ª¶ó´Â ¾ÆÁ÷¡¦ ÀÌÁö¿¬ 2020-12-22 94
84 ¹Ì±¹¡¤¿µ±¹ ¾à»ç, ¿Â¶óÀÎÀ¸·Î ¾î¶»°Ô °øºÎÇϳª ±è¼±Èñ 2020-12-16 96
83 ÀǾàǰÁ¤Ã¥¿¬ "¿Â¶óÀÎ ¿¬¼ö±³À°¿¡ CPD µµÀÔÇØ¾ß" ±è¼±Èñ 2020-12-16 91
82 [´ëÇѾà»çÀú³Î] CPD °³³ä µîÀå 80³â, ¿ì¸®³ª¶ó´Â ¾ÆÁ÷¡¦ ÀÌÁö¿¬ 2020-12-16 78
81 [´ëÇѾà»çÀú³Î] Áö¿ª ¿©°Ç ¸ÂÃá 'Ä¡¸Å¾È½É¸¶À»'+'Ä¡¸Å¾È½É¾à±¹' ¿î¿µ ÀÌÁö¿¬ 2020-12-08 98
80 [´ëÇѾà»çÀú³Î] È£ÁÖ ¾à±¹ÀÇ Ä¡¸Å Äɾî Àü·«Àº? ÀÌÁö¿¬ 2020-12-01 110
79 [¾à»ç°ø·Ð] Ä¡¸Å±¹°¡Ã¥ÀÓÁ¦ '¿Ö ¾à»ç´Â ºüÁ³À»±î'¡¦¿Ü±¹Àº ¾î¶»°Ô? ±è¼±Èñ 2020-11-25 130
78 [µ¥Àϸ®ÆÊ] ³â µÚ Ä¡¸ÅÀα¸ 100¸¸ ½Ã´ë¡¦¾à±¹ ¿ªÇÒÀ» ã¾Æ¶ó ±è¼±Èñ 2020-11-25 131

ÀÌÀü 10ÆäÀÌÁö [1]  [2]  [3]  [4]  [5]  [6]  [7]  ´ÙÀ½ 10ÆäÀÌÁö

 
 

¼­¿ï ¼­Ãʱ¸ È¿·É·Î194, 3Ãþ (Àç)ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò TEL : 02) 3474-5301 / FAX : 02)3474-5306

COPYRIGHT (C) 2006 KOREA INSTITUTE FOR PHARMACEUTICAL POLICY AFFAIRS ALL RIGHTS RESERVED. FOR MORE INFORMATION MAL kippa.org@gmail.com

±âºÎ±Ý ¾È³»